GlobeNewswire Inc | Jan 6, 2021 05:00PM EST

January 06, 2021

TORONTO and CHICAGO and MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that it has engaged Independent Trading Group (ITG), Inc. (ITG) to provide market-making services to the Company in accordance with TSX Venture Exchange (TSXV) policies. ITG will trade the Companys common shares (the Common Shares) on the TSXV and other marketplaces, as applicable, with the objective of maintaining a reasonable market and improving the liquidity of the Common Shares.

Pursuant to the terms of a services agreement (the Services Agreement), ITG will receive compensation of C$5,000 per month (plus applicable taxes), payable on the first business day of each month, for an initial term of three months, with services commencing on January 6, 2021. The Services Agreement will automatically renew for additional one-month terms unless terminated by either party in accordance with the terms and conditions of the Services Agreement. The Services Agreement may be terminated by either party with 30 days notice.

There are no performance factors contained in the Services Agreement and ITG will not receive any Common Shares or other securities of the Company as compensation for the services it will render to the Company. As of the date hereof, ITG and the Company are unaffiliated entities and neither ITG nor its principals have an interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Companys vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Companys leading products are: Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall, an innovative allergy medication with a unique mode of action.

For more information, please contact:

Ken dEntremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:ken.dentremont@medexus.com

Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail:roland.boivin@medexus.com

Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email:mdp@crescendo-ir.com

Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail:tina@adcap.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.